Surrozen registers resale of up to 5,741,605 common shares, 2,456,500 pre-funded warrant shares and 4,099,052 Series E warrant shares, bought in an October 20, 2026 tranche of its private placement for approximately $95.1 million gross. The company receives no resale proceeds, but would receive approximately $47.3 million if all warrants are exercised for cash. Proceeds are intended for development of SZN-8141 and SZN-8143.
SRZN · Surrozen, Inc.
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
Key stats
- Short volume, last session
- 53%
- Last earnings
- Mar 22, 2023
- Latest filing
- 10-Q · Nov 9
- Price history
- Jan 2021 to Nov 2026
Up next
Latest documents
Surrozen, Inc. agreed to sell 1,894,540 common shares at $31.67 per share, generating expected gross proceeds of approximately $60 million before discounts and expenses; closing is expected November 16, 2026.
Surrozen expanded its 8141 diabetic macular edema study to about 150 patients, dosed the first patient in the single dose portion and expects 2027 data. About $220 million is expected to fund operations into 2029.
Surrozen received FDA clearance for SZN-8141 in October 2026 and dosed its first patient in the DUET Phase 1b/2a study. It reported a $207.1 million nine-month net loss, $100.4 million cash, and a cash runway into 2029.
Surrozen dosed the first patient in the DUET Phase 1b study and plans to expand Phase 2a enrollment from approximately 60 to 150 patients. Third-quarter net loss was $129.7 million, and anticipated cash runway extends into 2029.
Metrics snapshot
Useful current figures from the complete screener profile.
Quarterly results
* Q4 derived as the full year minus Q1 to Q3.
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders NeutralIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| At-the-market offering net proceeds | $29.8M | October 2026 | — |
| gross proceeds | $0.8M | the three months ended September 30, 2026 filing | — |
| March 2025 private placement second tranche gross proceeds | $95.1M | October 2026 | — |
| net proceeds | $26.9M | the first quarter of 2026 filing | — |
| Pro forma cash and cash equivalents | $220.3M | as of September 30, 2026 | — |
| Second tranche of March 2025 PIPE and ATM net proceeds | $118.9M | October 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
SRZN
this stock
Surrozen, Inc.
|
$542.49M | +25.9% | -67.4% | — | 17.0% |
|
VRTX
Vertex Pharmaceuticals Inc
|
$130.58B | +13.6% | +46.2% | 33.2 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$95.24B | +19.3% | +20.8% | 20.4 | 2.1% |
|
MRNA
Moderna, Inc.
|
$78.90B | +561.2% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$62.17B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- Filed
- Nov 18, 2026
- This year
- 22
Surrozen registers resale of up to 5,741,605 common shares, 2,456,500 pre-funded warrant shares and 4,099,052 Series E warrant shares, bought in an October 20, 2026 tranche of its private placement for approximately $95.1 million gross. The company receives no resale proceeds, but would receive approximately $47.3 million if all warrants are exercised for cash. Proceeds are intended for development of SZN-8141 and SZN-8143.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| SRZN | -10.0% | +11.7% | +23.0% | -2.0% | +25.9% |
| SPY | -8.6% | -9.2% | -9.2% | -8.7% | +1.2% |
| vs SPY | -1.4% | +20.9% | +32.1% | +6.7% | +24.8% |